{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:26:11Z","timestamp":1792070771836,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,16]]},"DOI":"10.7759\/cureus.92454","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T14:47:34Z","timestamp":1758034054000},"source":"Crossref","is-referenced-by-count":14,"title":["Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Omar A","family":"Alsuwailem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hessa M","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan H","family":"Asiree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasan","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taghreed M","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"Zamandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh","family":"Alkhames","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity","volume":"1307","author":"Maselli DB","year":"2021","unstructured":"Maselli DB, Camilleri M. Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity. Adv Exp Med Biol. 2021, 1307:171-92. 10.1007\/5584_2020_496","journal-title":"Adv Exp Med Biol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2024.01.010","article-title":"GLP-1 agonists: a review for emergency clinicians","volume":"78","author":"Long B","year":"2024","unstructured":"Long B, Pelletier J, Koyfman A, Bridwell RE. GLP-1 agonists: a review for emergency clinicians. Am J Emerg Med. 2024, 78:89-94. 10.1016\/j.ajem.2024.01.010","journal-title":"Am J Emerg Med"},{"key":"ref3","article-title":"Glucagon-like peptide-1 receptor agonists","author":"Collins L","year":"2024","unstructured":"Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Vilsb\u00f8ll T","year":"2012","unstructured":"Vilsb\u00f8ll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012, 344:d7771. 10.1136\/bmj.d7771","journal-title":"BMJ"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.16716","article-title":"The Role of GLP-1 agonists in esthetic medicine: exploring the impact of semaglutide on body contouring and skin health","volume":"24","author":"Haykal D","year":"2025","unstructured":"Haykal D, Hersant B, Cartier H, Meningaud JP. The Role of GLP-1 agonists in esthetic medicine: exploring the impact of semaglutide on body contouring and skin health. J Cosmet Dermatol. 2025, 24:e16716. 10.1111\/jocd.16716","journal-title":"J Cosmet Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-024-07613-w","article-title":"Risk of suicide, hair loss, and aspiration with GLP1-receptor agonists and other diabetic agents: a real-world pharmacovigilance study","author":"Nakhla M","year":"2024","unstructured":"Nakhla M, Nair A, Balani P, et al.. Risk of suicide, hair loss, and aspiration with GLP1-receptor agonists and other diabetic agents: a real-world pharmacovigilance study. Cardiovasc Drugs Ther. 2024, 10.1007\/s10557-024-07613-w","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.03.021","article-title":"Dermatologic findings associated with semaglutide use: a scoping review","volume":"91","author":"Tran MM","year":"2024","unstructured":"Tran MM, Mirza FN, Lee AC, Goldbach HS, Libby TJ, Wisco OJ. Dermatologic findings associated with semaglutide use: a scoping review. J Am Acad Dermatol. 2024, 91:166-8. 10.1016\/j.jaad.2024.03.021","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00941-z","article-title":"The invisible impact of a visible disease: psychosocial impact of alopecia areata","volume":"13","author":"Mesinkovska N","year":"2023","unstructured":"Mesinkovska N, Craiglow B, Ball SG, Morrow P, Smith SG, Pierce E, Shapiro J. The invisible impact of a visible disease: psychosocial impact of alopecia areata. Dermatol Ther (Heidelb). 2023, 13:1503-15. 10.1007\/s13555-023-00941-z","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S486039","article-title":"Awareness, beliefs, and psychological impact of patients with alopecia areata in Saudi Arabia: a multi-center study","volume":"18","author":"Almulhim NA","year":"2024","unstructured":"Almulhim NA, Alojail HY, Aljughayman MA, et al.. Awareness, beliefs, and psychological impact of patients with alopecia areata in Saudi Arabia: a multi-center study. Patient Prefer Adherence. 2024, 18:2597-607. 10.2147\/PPA.S486039","journal-title":"Patient Prefer Adherence"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.047","article-title":"Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review","volume":"85","author":"Toussi A","year":"2021","unstructured":"Toussi A, Barton VR, Le ST, Agbai ON, Kiuru M. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review. J Am Acad Dermatol. 2021, 85:162-75. 10.1016\/j.jaad.2020.06.047","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-017-0663-8","article-title":"Evaluations of the uptake and impact of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement and extensions: a scoping review","volume":"6","author":"Page MJ","year":"2017","unstructured":"Page MJ, Moher D. Evaluations of the uptake and impact of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement and extensions: a scoping review. Syst Rev. 2017, 6:263. 10.1186\/s13643-017-0663-8","journal-title":"Syst Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2165","article-title":"The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons","volume":"7","author":"Nejadghaderi SA","year":"2024","unstructured":"Nejadghaderi SA, Balibegloo M, Rezaei N. The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons. Health Sci Rep. 2024, 7:e2165. 10.1002\/hsr2.2165","journal-title":"Health Sci Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.11124\/JBISRIR-D-19-00099","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn Z","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, et al.. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020, 18:2127-33. 10.11124\/JBISRIR-D-19-00099","journal-title":"JBI Evid Synth"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-025-05084-7","article-title":"Systematic review of case series and case reports on pediatric pulmonary embolism","volume":"19","author":"Alsabri M","year":"2025","unstructured":"Alsabri M, Attalla A, Abdelrahman ST, et al.. Systematic review of case series and case reports on pediatric pulmonary embolism. J Med Case Rep. 2025, 19:76. 10.1186\/s13256-025-05084-7","journal-title":"J Med Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.01.046","article-title":"Glucagon-like peptide-1 receptor agonist medications and hair loss: a retrospective cohort study","volume":"92","author":"Burke O","year":"2025","unstructured":"Burke O, Sa B, Cespedes DA, Sechi A, Tosti A. Glucagon-like peptide-1 receptor agonist medications and hair loss: a retrospective cohort study. J Am Acad Dermatol. 2025, 92:1141-3. 10.1016\/j.jaad.2025.01.046","journal-title":"J Am Acad Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.04.058","article-title":"GLP-1 agonists may modulate treatment efficacy in central centrifugal cicatricial alopecia","volume":"93","author":"Desir N","year":"2025","unstructured":"Desir N, Encarnacion IN, Schell N, Anusionwu I, Ogunleye TA, Taylor SC. GLP-1 agonists may modulate treatment efficacy in central centrifugal cicatricial alopecia. J Am Acad Dermatol. 2025, 93:771-3. 10.1016\/j.jaad.2025.04.058","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.76267","article-title":"Improvement of recalcitrant folliculitis decalvans with tirzepatide: a case report","volume":"16","author":"Morrissette K","year":"2024","unstructured":"Morrissette K, Hansen S, Pavlis M, Murray JC. Improvement of recalcitrant folliculitis decalvans with tirzepatide: a case report. Cureus. 2024, 16:e76267. 10.7759\/cureus.76267","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.06.001","article-title":"Treatment of insulin resistance with tirzepatide leading to improvement of hair loss","volume":"50","author":"Gordon ER","year":"2024","unstructured":"Gordon ER, Musleh S, Bordone LA. Treatment of insulin resistance with tirzepatide leading to improvement of hair loss. JAAD Case Rep. 2024, 50:123-5. 10.1016\/j.jdcr.2024.06.001","journal-title":"JAAD Case Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17246","article-title":"GLP-1 agonists and hair loss: a call for further investigation","volume":"63","author":"Desai DD","year":"2024","unstructured":"Desai DD, Sikora M, Nohria A, Bordone L, Caplan AS, Shapiro J, Lo Sicco KI. GLP-1 agonists and hair loss: a call for further investigation. Int J Dermatol. 2024, 63:1128-30. 10.1111\/ijd.17246","journal-title":"Int J Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2006.02.007","article-title":"Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin","volume":"134","author":"List JF","year":"2006","unstructured":"List JF, He H, Habener JF. Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin. Regul Pept. 2006, 134:149-57. 10.1016\/j.regpep.2006.02.007","journal-title":"Regul Pept"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20197","article-title":"Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023","volume":"39","author":"Godfrey H","year":"2025","unstructured":"Godfrey H, Leibovit-Reiben Z, Jedlowski P, Thiede R. Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol. 2025, 39:e153-4. 10.1111\/jdv.20197","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102661","article-title":"GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study","volume":"73","author":"Moll H","year":"2024","unstructured":"Moll H, Frey E, Gerber P, et al.. GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study. EClinicalMedicine. 2024, 73:102661. 10.1016\/j.eclinm.2024.102661","journal-title":"EClinicalMedicine"},{"key":"ref24","unstructured":"Novo Nordisk. Wegovy \u00ae product monograph. Accessed. February 15, 2024: https:\/\/www.novonordisk.ca\/content\/dam\/nncorp\/ca\/en\/products\/Wegovy-product-monograph.pdf."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.70125","article-title":"Alopecia and semaglutide: connecting the dots for patient safety","volume":"24","author":"Haykal D","year":"2025","unstructured":"Haykal D. Alopecia and semaglutide: connecting the dots for patient safety. J Cosmet Dermatol. 2025, 24:e70125. 10.1111\/jocd.70125","journal-title":"J Cosmet Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies","volume":"27 Suppl 2","author":"Thomsen RW","year":"2025","unstructured":"Thomsen RW, Mailhac A, L\u00f8hde JB, Potteg\u00e5rd A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025, 27 Suppl 2:66-88. 10.1111\/dom.16364","journal-title":"Diabetes Obes Metab"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S136639","article-title":"Cost of medication adherence and persistence in type 2 diabetes mellitus: a literature review","volume":"11","author":"Kennedy-Martin T","year":"2017","unstructured":"Kennedy-Martin T, Boye KS, Peng X. Cost of medication adherence and persistence in type 2 diabetes mellitus: a literature review. Patient Prefer Adherence. 2017, 11:1103-17. 10.2147\/PPA.S136639","journal-title":"Patient Prefer Adherence"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/402023-hair-loss-associated-with-glucagon-like-peptide-1-glp-1-receptor-agonist-use-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T14:47:35Z","timestamp":1758034055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/402023-hair-loss-associated-with-glucagon-like-peptide-1-glp-1-receptor-agonist-use-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.92454","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,16]]}}}